Abstract
The emergence of SARS-CoV-2 variants of concern suggests viral adaptation to enhance human-to-human transmission1,2. Although much effort has focused on the characterization of changes in the spike protein in variants of concern, mutations outside of spike are likely to contribute to adaptation. Here, using unbiased abundance proteomics, phosphoproteomics, RNA sequencing and viral replication assays, we show that isolates of the Alpha (B.1.1.7) variant3 suppress innate immune responses in airway epithelial cells more effectively than first-wave isolates. We found that the Alpha variant has markedly increased subgenomic RNA and protein levels of the nucleocapsid protein (N), Orf9b and Orf6—all known innate immune antagonists. Expression of Orf9b alone suppressed the innate immune response through interaction with TOM70, a mitochondrial protein that is required for activation of the RNA-sensing adaptor MAVS. Moreover, the activity of Orf9b and its association with TOM70 was regulated by phosphorylation. We propose that more effective innate immune suppression, through enhanced expression of specific viral antagonist proteins, increases the likelihood of successful transmission of the Alpha variant, and may increase in vivo replication and duration of infection4. The importance of mutations outside the spike coding region in the adaptation of SARS-CoV-2 to humans is underscored by the observation that similar mutations exist in the N and Orf9b regulatory regions of the Delta and Omicron variants.
Original language | English |
---|---|
Pages (from-to) | 487-495 |
Number of pages | 9 |
Journal | Nature |
Volume | 602 |
Issue number | 7897 |
DOIs | |
State | Published - 17 Feb 2022 |
Access to Document
Fingerprint
Dive into the research topics of 'Evolution of enhanced innate immune evasion by SARS-CoV-2'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature, Vol. 602, No. 7897, 17.02.2022, p. 487-495.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Evolution of enhanced innate immune evasion by SARS-CoV-2
AU - Thorne, Lucy G.
AU - Bouhaddou, Mehdi
AU - Reuschl, Ann Kathrin
AU - Zuliani-Alvarez, Lorena
AU - Polacco, Ben
AU - Pelin, Adrian
AU - Batra, Jyoti
AU - Whelan, Matthew V.X.
AU - Hosmillo, Myra
AU - Fossati, Andrea
AU - Ragazzini, Roberta
AU - Jungreis, Irwin
AU - Ummadi, Manisha
AU - Rojc, Ajda
AU - Turner, Jane
AU - Bischof, Marie L.
AU - Obernier, Kirsten
AU - Braberg, Hannes
AU - Soucheray, Margaret
AU - Richards, Alicia
AU - Chen, Kuei Ho
AU - Harjai, Bhavya
AU - Memon, Danish
AU - Hiatt, Joseph
AU - Rosales, Romel
AU - McGovern, Briana L.
AU - Jahun, Aminu
AU - Fabius, Jacqueline M.
AU - White, Kris
AU - Goodfellow, Ian G.
AU - Takeuchi, Yasu
AU - Bonfanti, Paola
AU - Shokat, Kevan
AU - Jura, Natalia
AU - Verba, Klim
AU - Noursadeghi, Mahdad
AU - Beltrao, Pedro
AU - Kellis, Manolis
AU - Swaney, Danielle L.
AU - García-Sastre, Adolfo
AU - Jolly, Clare
AU - Towers, Greg J.
AU - Krogan, Nevan J.
N1 - Funding Information: Competing interests The N.J.K. laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. N.J.K. has consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics and Interline Therapeutics. He is a shareholder in Tenaya Therapeutics, Maze Therapeutics and Interline Therapeutics, has received stocks from Maze Therapeutics and Interline Therapeutics and is a financially compensated Scientific Advisory Board Member for GEn1E Lifesciences. The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold, Model Medicines, Atea Pharma and Merck. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, Paratus and Pfizer. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections, owned by the Icahn School of Medicine at Mount Sinai, New York. Funding Information: This research was funded by grants from the National Institutes of Health (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694 and P01AI063302 to N.J.K.; F32CA239333 to M.B.; R01GM133981 to D.L.S.); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between UCSF, UCB and GSK (133122P); by the Roddenberry Foundation; by funding from F. Hoffmann-La Roche and Vir Biotechnology; and through gifts from QCRG philanthropic donors. This research was also partly funded by the Center for Research on Influenza Pathogenesis (CRIP), a NIAID funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract no. HHSN272201400008C), and the Center for Research on Influenza Pathogenesis and Transmission (CRIPT), a NIAID funded Center of Excellence for Influenza Research and Response (CEIRR, contract no. 75N93021C00014); by NCI SeroNet grant U54CA260560; and by the support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)) and anonymous donors to A.G.-S. This work was also supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement no. HR0011-19-2-0020. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. G.J.T. was funded by Wellcome Senior Fellowship 108183 followed by Wellcome Investigator Award 220863. C.J. was funded by Wellcome Investigator Award 108079 followed by 223065. G.J.T. and C.J. were funded by MRC/UKRI G2P-UK National Virology consortium (MR/W005611/1) and the UCL COVID-19 fund. M.N. was funded by Wellcome Investigator Award 207511. I.G.G. is a Wellcome Senior Fellow and this work was supported by grants from the Wellcome Trust (refs: 207498 and 206298). P.?Bonfanti?received funding from the European Research Council (ERC-Stg no. 639429), the Rosetrees Trust (M362-F1; M553) and the CF Trust (SRC006; SRC020); R.?Ragazzini?is supported by a Marie Sk?odowska-Curie Individual Fellowships no.?896014.?Funds were also obtained from the National Institutes of Health Research UCL/UCLH Biomedical Research Centre. M.V.X.W. is supported by the NIHR Biomedical Research Centre at UCLH and IDEA Bio-Medical. We are grateful to the National Institute of Health Research Health Protection Research Unit in Respiratory Infections (NIHR 200927) and the Assessment of Transmission and Contagiousness of COVID-19 in Contacts (ATACCC) Study funded by the DHSC COVID-19 Fighting Fund. We are also grateful to the ATACCC investigators, in particular A. Lalvani, J. Dunning, J. Fenn, R. Kundu, R. Varro, S. Hammett, J. Cutajaar, E. McDermott, J. Samuel, S. Bremang, A. Koycheva, N. Fernandez Derqui, S. Janakan, E. Conibear, L. Wang, S. Hakki, M. Zambon, J. Ellis, A. Lackenby, S. Miah and colleagues at Public Health England, G. Mattiuzzo at the National Institute for Biological Standards and Controls and W. Barclay and J. Brown at Imperial College London for provision of variant isolates, reagents and advice. We are grateful to R. Milne for discussions and critical reading of the manuscript. Funding Information: Acknowledgements This research was funded by grants from the National Institutes of Health (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694 and P01AI063302 to N.J.K.; F32CA239333 to M.B.; R01GM133981 to D.L.S.); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between UCSF, UCB and GSK (133122P); by the Roddenberry Foundation; by funding from F. Hoffmann-La Roche and Vir Biotechnology; and through gifts from QCRG philanthropic donors. This research was also partly funded by the Center for Research on Influenza Pathogenesis (CRIP), a NIAID funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract no. HHSN272201400008C), and the Center for Research on Influenza Pathogenesis and Transmission (CRIPT), a NIAID funded Center of Excellence for Influenza Research and Response (CEIRR, contract no. 75N93021C00014); by NCI SeroNet grant U54CA260560; and by the support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)) and anonymous donors to A.G.-S. This work was also supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement no. HR0011-19-2-0020. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. G.J.T. was funded by Wellcome Senior Fellowship 108183 followed by Wellcome Investigator Award 220863. C.J. was funded by Wellcome Investigator Award 108079 followed by 223065. G.J.T. and C.J. were funded by MRC/UKRI G2P-UK National Virology consortium (MR/W005611/1) and the UCL COVID-19 fund. M.N. was funded by Wellcome Investigator Award 207511. I.G.G. is a Wellcome Senior Fellow and this work was supported by grants from the Wellcome Trust (refs: 207498 and 206298). P. Bonfanti received funding from the European Research Council (ERC-Stg no. 639429), the Rosetrees Trust (M362-F1; M553) and the CF Trust (SRC006; SRC020); R. Ragazzini is supported by a Marie Skłodowska-Curie Individual Fellowships no. 896014. Funds were also obtained from the National Institutes of Health Research UCL/UCLH Biomedical Research Centre. M.V.X.W. is supported by the NIHR Biomedical Research Centre at UCLH and IDEA Bio-Medical. We are grateful to the National Institute of Health Research Health Protection Research Unit in Respiratory Infections (NIHR 200927) and the Assessment of Transmission and Contagiousness of COVID-19 in Contacts (ATACCC) Study funded by the DHSC COVID-19 Fighting Fund. We are also grateful to the ATACCC investigators, in particular A. Lalvani, J. Dunning, J. Fenn, R. Kundu, R. Varro, S. Hammett, J. Cutajaar, E. McDermott, J. Samuel, S. Bremang, A. Koycheva, N. Fernandez Derqui, S. Janakan, E. Conibear, L. Wang, S. Hakki, M. Zambon, J. Ellis, A. Lackenby, S. Miah and colleagues at Public Health England, G. Mattiuzzo at the National Institute for Biological Standards and Controls and W. Barclay and J. Brown at Imperial College London for provision of variant isolates, reagents and advice. We are grateful to R. Milne for discussions and critical reading of the manuscript. Publisher Copyright: © 2021, The Author(s).
PY - 2022/2/17
Y1 - 2022/2/17
N2 - The emergence of SARS-CoV-2 variants of concern suggests viral adaptation to enhance human-to-human transmission1,2. Although much effort has focused on the characterization of changes in the spike protein in variants of concern, mutations outside of spike are likely to contribute to adaptation. Here, using unbiased abundance proteomics, phosphoproteomics, RNA sequencing and viral replication assays, we show that isolates of the Alpha (B.1.1.7) variant3 suppress innate immune responses in airway epithelial cells more effectively than first-wave isolates. We found that the Alpha variant has markedly increased subgenomic RNA and protein levels of the nucleocapsid protein (N), Orf9b and Orf6—all known innate immune antagonists. Expression of Orf9b alone suppressed the innate immune response through interaction with TOM70, a mitochondrial protein that is required for activation of the RNA-sensing adaptor MAVS. Moreover, the activity of Orf9b and its association with TOM70 was regulated by phosphorylation. We propose that more effective innate immune suppression, through enhanced expression of specific viral antagonist proteins, increases the likelihood of successful transmission of the Alpha variant, and may increase in vivo replication and duration of infection4. The importance of mutations outside the spike coding region in the adaptation of SARS-CoV-2 to humans is underscored by the observation that similar mutations exist in the N and Orf9b regulatory regions of the Delta and Omicron variants.
AB - The emergence of SARS-CoV-2 variants of concern suggests viral adaptation to enhance human-to-human transmission1,2. Although much effort has focused on the characterization of changes in the spike protein in variants of concern, mutations outside of spike are likely to contribute to adaptation. Here, using unbiased abundance proteomics, phosphoproteomics, RNA sequencing and viral replication assays, we show that isolates of the Alpha (B.1.1.7) variant3 suppress innate immune responses in airway epithelial cells more effectively than first-wave isolates. We found that the Alpha variant has markedly increased subgenomic RNA and protein levels of the nucleocapsid protein (N), Orf9b and Orf6—all known innate immune antagonists. Expression of Orf9b alone suppressed the innate immune response through interaction with TOM70, a mitochondrial protein that is required for activation of the RNA-sensing adaptor MAVS. Moreover, the activity of Orf9b and its association with TOM70 was regulated by phosphorylation. We propose that more effective innate immune suppression, through enhanced expression of specific viral antagonist proteins, increases the likelihood of successful transmission of the Alpha variant, and may increase in vivo replication and duration of infection4. The importance of mutations outside the spike coding region in the adaptation of SARS-CoV-2 to humans is underscored by the observation that similar mutations exist in the N and Orf9b regulatory regions of the Delta and Omicron variants.
UR - http://www.scopus.com/inward/record.url?scp=85121650670&partnerID=8YFLogxK
U2 - 10.1038/s41586-021-04352-y
DO - 10.1038/s41586-021-04352-y
M3 - Article
C2 - 34942634
AN - SCOPUS:85121650670
SN - 0028-0836
VL - 602
SP - 487
EP - 495
JO - Nature
JF - Nature
IS - 7897
ER -